Hungarian startup Oncompass Medicine– n AI-based medical software to choose the targeted cancer therapy — beat two Nordic startups in the final of annual “Future Unicorn Award,” Europe’s largest trade association DigitalEurope said.
“There is huge innovation potential in Europe, but companies are often held back by lack of investment, outdated regulation or market fragmentation. To reach our goal of Europe being home to 25 percent of the world’s unicorns, it is essential that policymakers create the conditions for companies like Oncompass Medicine to grow,” Director-General Cecilia Bonefeld-Dahl said in a statement.
“We will work hard to fulfill the expectation this prize represents and find the right therapy for as many cancer patients as possible,” said Istvan Petak, founder of Oncompass Medicine.
“I want to congratulate the other two finalists and all the nominees and express my gratitude for their contribution to our better future,” Petak said.
The other finalists were Exeger from Sweden – the inventor and producer of a patented solar cell technology, and Ocean Sun from Norway – A solution provider and design architect for floating solar power plants.
Running for the fourth year in a row, the “Future Unicorn Award” celebrates scale-ups from across Europe that have the potential to become the future European tech giants. It is compiled in collaboration with DigitalEurope’s national trade associations.
This year, 21 companies from 17 European countries were nominated for the award, representing a variety of digitally-transforming sectors, including financial technologies, education technologies, e-health, energy, security and more.
